Why Is HIMS & HERS HEALTH I A (HIMS) Stock Down Today?

HIMS stock closed down 4.00% at $30.48 on Tuesday, marking its worst day in a month. The decline followed a warning from Visa, which placed the company in its Acquirer Monitoring Program due to an elevated rate of billing disputes. This action triggered additional penalty costs and raised concerns about the company’s ability to manage its payment processing risks amid ongoing regulatory scrutiny and margin pressures.

What Happened

Visa flagged Hims & Hers for a dispute rate above 1.5%, triggering a $75,000 surcharge and the need for the company to reduce the rate to acceptable levels. This development came alongside a separate FTC lawsuit and reports of margin contraction. The stock opened at $31.60 but quickly declined, hitting a session low of $30.38 before closing at $30.45. Multiple law firms have also announced ongoing investigations into potential securities fraud, adding to investor uncertainty.

Several analysts have weighed in on the stock’s future. Truist Securities raised its price target to $32 and maintained a Hold rating, while Barclays cut its target to $35 and kept an Overweight stance. Hims & Hers management is also meeting with KeyBanc for a virtual session, suggesting ongoing efforts to address investor concerns. The company has rejected privacy allegations and pledged to expand patient access, but these statements have not yet stabilized the stock.

What The Data Shows

The stock has traded with elevated volatility, opening near $31.60 but declining throughout the session. Volume was 2.2 million shares, which is 0.1x the 3-month daily average. Over the last 8 sessions, the stock had risen 11.3% from $28.58 to $31.82. Unusual options activity included four notable prints, with put premiums totaling $6.9 million and the largest single print at $2.9 million. The 30-day average sentiment score has declined from 47 to 43 over the last seven days. Recent insider transactions show 11 sales totaling $7.2 million in the last 90 days, with several executives selling shares in early August.

What To Watch

The company is scheduled to meet with KeyBanc in the coming days, and investors will be watching for further guidance on its dispute resolution and financial strategy. The stock’s performance may also be influenced by the outcome of ongoing legal and regulatory investigations.